Novartis highlights pioneering innovation in CML with data from Scemblix® Phase III ASC4FIRST study in newly diagnosed patients at ASCO and EHA
GlobeNewswire
· Primary results of the Scemblix^® ASC4FIRST pivotal Phase III study in first-line Ph+ CML-CP supporting third US FDA..